Doubling forces against glioblastomas: Two-drug combination slows malignant brain tumors in mice

Doubling Forces Against Glioblastomas
3-D rendering of the signaling domain of the murine Shh pathway. Credit: Protein Data Bank/Peter Znamenskiy

(Medical Xpress)—A novel combination of two oral targeted drugs dramatically slowed the growth of glioblastoma brain tumors in mice and significantly extended the animals' survival, report scientists at Harvard Medical School and Dana-Farber Cancer Institute.

The researchers paired two drugs that inhibit overactivity of two cell signaling pathways that drive many glioblastomas, the most lethal malignant brain tumors. Previous attempts to treat this type of glioblastoma by blocking just one of the pathways were unsuccessful. A report on the new study was posted online by Nature Medicine.

The combination targets a genetic abnormality found in about one-third of glioblastomas—: a mutation that disables PTEN, a tumor- suppressor gene. This strategy is relevant only to glioblastomas that aren't driven by the loss of PTEN. These Other tumors glioblastomas develop through a variety of other genetic flaws for which scientists are testing different targeted treatments.

Loss of the PTEN gene unleashes a chain reaction, with overactive molecular growth signals spurring cells into malignant growth; cells pile up to form aggressive tumors that infiltrate the brain. Scientists can't replace the PTEN gene to restore order; instead, they use drugs to block the excessive growth signaling that flows through gene networks.

Overactivity in a signaling pathway known as PI3K is a known culprit in glioblastomas lacking the PTEN gene, and drugs are available to inhibit PI3K activity. But drugs that block PI3K alone haven't had much success in slowing .

Looking for another chink in glioblastomas' defenses, the researchers, led by Rosalind Segal, HMS professor of neurobiology at Dana-Farber, found that another signaling pathway, known as sonic hedgehog or Shh, also is activated by PTEN loss and gangs up synergistically with PI3K. "You have a very strong dual gas pedal" fueling the cancer's growth, Segal said. That explained why treating the tumors with a single inhibitor that dampens PI3K signaling but not Shh signaling hasn't been effective for PTEN-deficient glioblastomas.

To test whether blocking both PI3K and Shh signaling simultaneously would have greater impact, the researchers tested inhibitor combinations on glioblastoma "neurospheres"—small clumps of human tumor cells grown in laboratory culture. Using several different targeted drugs, they showed that the strategy worked to slow growth in the tumor cells lacking PTEN but not in those where the was intact.

Next, the scientists injected human into mice, where they formed rapidly growing tumors, and compared the effects of administering either?? a dummy drug, a single drug that blocked PI3K, a single drug blocking Shh and a combination of inhibitors against PI3K and Shh. As anticipated, the two-drug combination shrank tumors and slowed their growth, and the animals lived much longer than those in the other three groups.

Segal noted that promising results in mice often fail to translate to humans, but said she's hopeful that the new strategy may contribute to more successful treatment of glioblastomas, which resist most current treatments and have a poor survival rate.

"These are oral drugs, taken in pill form once a day, and we know they cross the blood-brain barrier and reach the ," Segal said.

More information: www.nature.com/nm/journal/vaop… nt/full/nm.3328.html

Related Stories

Targeting cancer's sweet tooth

Oct 21, 2013

Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

Therapy exploits 'addiction' of leukemia cells

Apr 16, 2012

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online ...

Recommended for you

Video: Is that double mastectomy really necessary?

Oct 24, 2014

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym
not rated yet Oct 25, 2013
Dr. Jeffrey Hergenrather reports the case of a man diagnosed with a glioblastoma who was given six months to live via conventional therapies, but instead survived seven years (and counting as of the date of the interview) using only cannabis several times a day. While we wait for "The Cure" from Big Pharma, might it not be a good idea to allow people suffering from brain tumors access to a treatment that can be cheap, non-toxic and broadly effective?